Aimmune Therapeutics Inc (NASDAQ:AIMT) saw some unusual options trading on Tuesday. Traders purchased 2,062 put options on the stock. This represents an increase of approximately 1,474% compared to the typical daily volume of 131 put options.

Shares of AIMT stock opened at $21.56 on Wednesday. Aimmune Therapeutics has a fifty-two week low of $16.95 and a fifty-two week high of $36.12. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -5.87 and a beta of -0.07. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65. The business’s 50-day simple moving average is $19.51.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.08). During the same period last year, the firm posted ($0.91) earnings per share. As a group, equities analysts expect that Aimmune Therapeutics will post -3.82 earnings per share for the current year.

Several equities analysts have issued reports on the company. Roth Capital assumed coverage on Aimmune Therapeutics in a research note on Friday, July 12th. They issued a “buy” rating and a $45.00 target price on the stock. Credit Suisse Group initiated coverage on Aimmune Therapeutics in a research note on Tuesday, May 21st. They issued an “outperform” rating and a $30.00 target price on the stock. BidaskClub upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 2nd. Royal Bank of Canada dropped their price target on Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, ValuEngine upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $42.50.

Several hedge funds have recently modified their holdings of AIMT. Legal & General Group Plc lifted its holdings in shares of Aimmune Therapeutics by 29.1% during the fourth quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 4,123 shares during the period. Botty Investors LLC acquired a new stake in shares of Aimmune Therapeutics during the first quarter worth about $2,505,000. Norges Bank acquired a new stake in shares of Aimmune Therapeutics during the fourth quarter worth about $6,035,000. DekaBank Deutsche Girozentrale lifted its holdings in shares of Aimmune Therapeutics by 21.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 2,700 shares during the period. Finally, Pearl River Capital LLC acquired a new stake in shares of Aimmune Therapeutics during the first quarter worth about $28,000. Institutional investors and hedge funds own 75.85% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Article: How to Invest in an Index Fund

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.